Diadema Partners’s AnaptysBio ANAB Stock Holding History

Diadema Partners’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-117,300	Closed	-$2.18M	–	100
2025 Q1	$2.18M	Buy	117,300 +17,300	+17%	+$289K	0.57%	41
2024 Q4	$1.32M	Buy	+100,000	New	+$2.42M	0.57%	46

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Diadema Partners's ANAB Position: Q4 2025 in Review

Diadema Partners sold out of AnaptysBio (ANAB) in Q4 2025, closing a stake of 3,295 shares — an estimated $101K sold.

Diadema Partners first reported a position in ANAB in Q3 2025 and held it in 1 quarter. The position peaked at $101K in Q3 2025. 179 funds tracked by Wall St. Rank hold ANAB as of Q4 2025.

Diadema Partners reported no remaining AnaptysBio position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 3,295 AnaptysBio shares in Q4 2025, an estimated $101K.
Diadema Partners first reported a position in AnaptysBio in Q3 2025 and held it in 1 quarter.
Diadema Partners's AnaptysBio position peaked at $101K in Q3 2025.
179 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.